Boundless Bio Overview
- Year Founded
-
2018
- Status
-
Public
- Employees
-
82
- Stock Symbol
-
BOLD
- Share Price
-
$1.19
- (As of Friday Closing)
Boundless Bio General Information
Description
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.
Contact Information
Website
www.boundlessbio.comCorporate Office
- 10955 Alexandria Way
- Suite 100
- San Diego, CA 92121
- United States
Corporate Office
- 10955 Alexandria Way
- Suite 100
- San Diego, CA 92121
- United States
Boundless Bio Timeline
Boundless Bio Stock Performance
As of 11-Jul-2025, Boundless Bio’s stock price is $1.19. Its current market cap is $26.4M with 22.4M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.19 | $1.18 | $1.00 - $4.72 | $26.4M | 22.4M | 171K | -$2.85 |
Boundless Bio Financials Summary
As of 31-Mar-2025, Boundless Bio has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 31-Mar-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
|---|---|---|---|---|
| EV | (70,809) | (102,344) | ||
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (72,607) | (72,155) | (53,759) | (45,627) |
| Net Income | (65,691) | (65,363) | (49,434) | (45,901) |
| Total Assets | 191,242 | 206,409 | 129,894 | 76,829 |
| Total Debt | 48,574 | 47,632 | 2,195 | 5,183 |
Boundless Bio Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Boundless Bio Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Boundless Bio Comparisons
Industry
Financing
Details
Boundless Bio Competitors (32)
One of Boundless Bio’s 32 competitors is NexImmune, a Formerly VC-backed company based in Gaithersburg, MD.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| NexImmune | Formerly VC-backed | Gaithersburg, MD | ||||
| Kite Pharma | Formerly VC-backed | Santa Monica, CA | ||||
| Senti Bio | Formerly VC-backed | South San Francisco, CA | ||||
| Intensity Therapeutics | Formerly PE-Backed | Shelton, CT | ||||
| Sernova | Corporation | London, Canada |
Boundless Bio Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Boundless Bio Patents
Boundless Bio Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20240285614-A1 | Phenol ribonucleotide reductase (rnr) inhibitors and uses thereof | Pending | 07-Feb-2023 | ||
| US-20240228459-A1 | Wee1 inhibitors and uses thereof | Pending | 22-Dec-2022 | ||
| AU-2023275712-A1 | Pyridine checkpoint kinase 1 (chk1) inhibitors and uses thereof | Pending | 24-May-2022 | ||
| EP-4532486-A1 | Pyridine checkpoint kinase 1 (chk1) inhibitors and uses thereof | Pending | 24-May-2022 | ||
| US-20230272485-A1 | Replication stress pathway agent compositions and methods for treating cancer | Pending | 16-Feb-2022 | C12Q1/6886 |
Boundless Bio Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Boundless Bio ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
Boundless Bio FAQs
-
When was Boundless Bio founded?
Boundless Bio was founded in 2018.
-
Where is Boundless Bio headquartered?
Boundless Bio is headquartered in San Diego, CA.
-
What is the size of Boundless Bio?
Boundless Bio has 82 total employees.
-
What industry is Boundless Bio in?
Boundless Bio’s primary industry is Drug Discovery.
-
Is Boundless Bio a private or public company?
Boundless Bio is a Public company.
-
What is Boundless Bio’s stock symbol?
The ticker symbol for Boundless Bio is BOLD.
-
What is the current stock price of Boundless Bio?
As of 11-Jul-2025 the stock price of Boundless Bio is $1.19.
-
What is the current market cap of Boundless Bio?
The current market capitalization of Boundless Bio is $26.4M.
-
Who are Boundless Bio’s competitors?
NexImmune, Kite Pharma, Senti Bio, Intensity Therapeutics, and Sernova are some of the 32 competitors of Boundless Bio.
-
What is Boundless Bio’s annual earnings per share (EPS)?
Boundless Bio’s EPS for 12 months was -$2.85.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
